
Celtic Pharma committs £5m to Cantab
Celtic Pharma has invested £5m in biopharmaceutical company Cantab Biopharmaceuticals Limited.
The investment was made through Celtic's second fund, Celtic Pharma Holdings II LP.
Cambridge-based Cantab develops bio-superiors, which are next generation biologics designed to offer superior therapeutic efficacy and convenience over originator products.
The new funding will be used to target specific bio-superior opportunities in the area of haematology through its own resources and through agreements to access technology platforms from third parties. The initial capital commitment will be over three years, and is designed to allow Cantab to take its first biosuperior product into clinical trials.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater